NEWS & PERSPECTIVE
CAPItello-281: FDA approves capivasertib + abiraterone for PTEN-deficient advanced prostate cancer
The treatment landscape for advanced prostate cancer is rapidly shifting toward biomarker-driven precision strategies to overcome therapeutic resistance.1 Among molecularly defined subsets, phosphatase and tensin homolog (PTEN)-deficient tumors represent an aggressive phenotype prone to early progression on standard therapies.2 Following positive results from the phase 3 CAPItello-281 trial, the combination of capivasertib, abiraterone, and prednisone was approved by the United States Food & Drug Administration (FDA) as the first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer.1,3 By significantly prolonging radiographic progression-free survival (PFS), this regimen validates a landmark dual-pathway blockade strategy in precision urologic oncology.1
Prostate cancer is the second most common male malignancy worldwide, characterized by genomic heterogeneity that dictates clinical outcomes.4 Functional loss of PTEN occurs in around 20% of cases, accelerating disease progression and driving resistance to standard therapies.1,2 In alignment with Prostate Cancer Working Group 4 recommendations, this disease state is now designated as metastatic androgen pathway modulation-naïve or sensitive prostate cancer, replacing the historical term metastatic hormone-sensitive prostate cancer.5 Biologically, PTEN loss leads to uninhibited activation of the PI3K/AKT signaling pathway, supplying an androgen-independent proliferation signal.2 As suppressing androgen receptor signaling with abiraterone often triggers compensatory upregulation of the AKT pathway, combining abiraterone with the selective AKT inhibitor capivasertib achieves concurrent dual-pathway blockade, collapsing reciprocal survival mechanisms.1,2
The double-blind phase 3 CAPItello-281 trial evaluated this dual-pathway approach in 1,012 male patients presenting with de novo metastatic prostate cancer harboring histologically verified PTEN deficiency.1 Participants were randomized to receive capivasertib or placebo in combination with abiraterone, prednisone or prednisolone, and standard androgen deprivation therapy.1 The trial met its primary endpoint, demonstrating a statistically significant prolongation of investigator-assessed radiographic PFS in the capivasertib arm.1 Patients receiving capivasertib achieved a median radiographic progression-free survival of 33.2 months compared to 25.7 months for placebo, representing a 7.5-month absolute improvement and a 19% reduction in the risk of progression or death (HR=0.81; 95% CI: 0.66-0.98; p=0.034).1 Secondary endpoints corroborated these results, showing clinically meaningful extensions in time to castration resistance, time to prostate-specific antigen progression, and symptomatic skeletal event-free survival.1
The safety profile of the capivasertib and abiraterone combination was manageable and aligned with the established toxicological profiles of the individual drugs, showing no unexpected toxicities.1 The most common treatment-emergent adverse events were diarrhea, hyperglycemia, and maculopapular rash.1 Severe toxicities, classified as Grade 3 or higher events, developed primarily within the first twelve weeks of therapy.1 Proactive clinical measures, including anti-diarrheal therapy, routine blood glucose monitoring, and dose holds or reductions, successfully controlled these adverse effects.1 Consequently, overall treatment discontinuation rates specifically caused by toxicity remained low, confirming that the regimen can be safely integrated into clinical practice with appropriate supportive care.1
The approval of capivasertib combined with abiraterone highlights the growing necessity of baseline molecular profiling in advanced prostate cancer.1,3 Incorporating routine PTEN testing via immunohistochemistry or genomic profiling at initial diagnosis allows clinicians to identify patients who will benefit most from early targeted intervention.1,2 By replacing empirical treatment with biomarker-driven dual inhibition, oncologists can overcome treatment resistance, prolong disease control, and improve long-term therapeutic outcomes in patients facing PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostate cancer.1,5
